^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + STRN-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing

    Excerpt:
    ...A 43-year-old smoking man...Genotype by NGS showed EGFR exon19del and STRN-ALK fusion...gefitinib plus crizotinib and a partial response was achieved...The patient continued to respond to combined treatment of gefitinib plus crizotinib for 6 months…
    DOI:
    10.1016/j.jtho.2019.02.014